

NCIC CLINICAL TRIALS GROUP

GASTROINTESTINAL

DISEASE SITE COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Sunday, April 18, 2004 - 8:30 a.m. - 3:30 p.m.

Room: Churchill Ballroom A

Chair: Malcolm Moore

8:30 am	Welcome and Introduction	M Moore
8:35 am	CLOSED TRIALS [Brief comments]	Various
	CO.11 (SWOG 9304): Postoperative Evaluation of 5FU by Bolus Injection vs 5FU by Prolonged Venous Infusion Prior To and Following Combined Prolonged Venous Infusion Plus Pelvic Radiation Therapy vs Bolus 5FU Plus Leucovorin Plus Levamisole Prior To and Following Combined Pelvic Radiation Therapy Plus Bolus 5FU Plus Leucovorin in Patients with Rectal Cancer	
	CO.12 (NCCTG 93-46-53): A Prospective Randomized Trial Comparing Laparoscopic-Assisted Colectomy with Open Colectomy for Colon Cancer	
	CO.13 (NCCTG N9741): A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL) 5-Fluorouracil (%-FU), and Irinotecan (CPT-11) as Initial Treatment of Patients with Advanced Adenocarcinoma of the Colon and Rectum	
	CO.14 (CALGB 9581): Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A versus No Adjuvant Therapy Following Resection for Stage II (Modified Astler-Coller B2) Adenocarcinoma of the Colon	
	CO.15 (CALGB 89803): A Phase III Intergroup Trial of Irinotecan (CPT-11) Plus Fluorouracil (5-FU)/Leucovorin in Comparison to Fluorouracil/Leucovorin Alone After Surgery in Patients with Stage III Colon Cancer	
	PA.3 : A Randomized Placebo Controlled Study of OSI-774 (Tarceva™) Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer	
8:50 am	ACTIVE TRIALS	
	CO.16 (MRC CR07): Pathology-guided Treatment in Rectal Cancer - A randomised trial comparing pre-operative radiotherapy and selective post-operative chemoradiotherapy in rectal cancer	J Couture
	CO.17 : A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care versus Best Supportive Care in Patients with Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma	D Jonker
	ES.2 (TROG 03.01): A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-Radiotherapy	Rebecca Wong
	PA.2 (ESPAC-3): Adjuvant Chemotherapies in Resectable Pancreatic Cancer	S Gallinger/ M Moore
	BI.1 : A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) versus Gemcitabine Alone in Advanced Biliary Cancer	J Knox

continued . . .

9:45 am	IND REPORT	
	Closed Trials, Open Trials, Approved but not open trials, Future plans	Ralph Wong
10:00 am	ENDORSED CTSU TRIALS	
	PAC.1 (SWOG-S0205): A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer	Ralph Wong
	PAC.2 (ECOG-E4201): A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer	J Biagi
	GAC.1 (CALGB-80101): A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Adenocarcinoma	G Bjarnason
10:30 am	Refreshment Break	
10:45 am	PARTICIPATING IN CTSU TRIALS	S Riordan
11:00 am	DISEASE ORIENTED GROUP REPORTS / NEW TRIALS	
	Colon DOG	D Jonker
	CTSU trials for endorsement	
	Elderly/ less fit phase I/II capecitabine ± oral VEGF	C Cripps
	Adjuvant PTK in stage III colorectal cancer	M Moore/ D Lebowhl/ A Kay
	Other trials...	
	Esophageal DOG	Rebecca Wong / R Malthaner
	CTSU trials for endorsement	
	Other trials...	
12:00 pm	Lunch	
1:00 pm	DISEASE ORIENTED GROUP REPORTS / NEW TRIALS (continued)	
	Rectal DOG	J Brierley / J Couture
	CTSU trials for endorsement	
	A phase I/II study of the use of FDG as a radiation sensitizer in patients with locally advanced rectal cancer	Raimond Wong
	Other trials...	
	Pancreas/Stomach/Liver DOG	M Moore/ S Gallinger
	CTSU trials for endorsement	
	Neoadjuvant pancreas trial	A Wei
	Randomized phase II trial of Xelox + Avastin vs ECF in recurrent and/or metastatic gastroesophageal cancer	E Chen
	Other trials...	
2:00 pm	GI INTERGROUP UPDATE	
	Executive	M Moore
	Colon Task Force	D Jonker / M Moore
	Esophageal Task Force	Rebecca Wong
	Rectal Task Force	J Brierly
	Pancreas Task Force	M Moore
2:30 pm	DISCUSSION SESSION	
	Oxaliplatin, Avastin, Cetuximab.	M Moore

2:55 pm	Closing Remarks & Adjournment	M Moore
3:15 pm	Closed Session: GI Executive Meeting	M Moore